Clinical Trials Logo
  1. Home
  2. Other
  3. NCT00071409

Safety and Efficacy of INGAP-Peptide in Patients With Type 1 Diabetes

Diabetes Mellitus, Insulin-Dependent Clinical Trial

Official title:
A Randomized, Double-blind, Placebo-controlled, Rising Dose, Multicenter Study to Evaluate the Efficacy and Safety of 90 Days of 300 or 600 mg Daily Subcutaneous Injections of INGAP Peptide in Type I Diabetes Mellitus Patients

Clinical Trial Summary

Insulin is a chemical that the body needs in order to use or store sugar. It is made by a type of cell called a beta cell which resides in an organ known as the pancreas. Type 1 diabetes is a disease where the beta cells have been destroyed so that little or no insulin is made. Sugar levels rise in the blood as a result. INGAP-Peptide is being tested to attempt to create new beta cells in the pancreas, and to restore the ability to produce insulin in type 1 diabetic patients.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00071409
Study type Interventional
Source Exsulin Corporation
Contact
Status Completed
Phase Phase 2
Start date October 2003
Completion date May 2004
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT01322789 - Safety and Efficacy of Mesenchymal Stem Cells in Newly-diagnosed Type 1 Diabetic Patients Phase 1/Phase 2
Completed NCT00035750 - Risk Factors for Atherogenesis in Type 1 Diabetes N/A
Completed NCT00005754 - Coronary Artery Calcification in Type 1 Diabetes N/A
Completed NCT00005474 - Markers and Mechanisms of Macrovascular Disease in IDDM N/A
Completed NCT01236365 - Statins in Children With Type 1 Diabetes and Hypercholesterolemia Phase 3
Completed NCT01216618 - Evaluation of the Effect of the InsuPatch Device on Insulin Pharmacokinetics in Clamp Studies Phase 3
Completed NCT00069537 - Continuous Glucose Monitors for Children With Diabetes Mellitus Phase 4
Completed NCT05168657 - Feasibility of Closed-loop Automated Insulin Delivery System by Primary Care & Endocrinology, in Person & Via Telehealth N/A
Withdrawn NCT00297635 - Telemetric Glucose Data Acquisition During Initiation of Insulin Pump Therapy Phase 2
Completed NCT00184821 - Ischemic Injury and Ischemic Preconditioning in Diabetes N/A
Completed NCT00073255 - Safety and Pharmacokinetics (PK) of hOKT3g1 (Ala-Ala) in Type 1 Diabetes Mellitus (T1DM) Phase 1
Completed NCT00690066 - PROCHYMAL® (Human Adult Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus (T1DM) Phase 2
Active, not recruiting NCT04078308 - Mesenchymal Stem Cells Transplantation in Newly Diagnosed Type-1 Diabetes Patients Phase 1/Phase 2
Completed NCT00069628 - Randomized Clinical Trial to Assess the Effectiveness of the GlucoWatch Biographer Phase 4
Completed NCT00044408 - Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes Phase 3
Completed NCT00044395 - Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes Phase 3
Completed NCT00069615 - Pilot Study of the GlucoWatch G2 Biographer for the Management of Type 1 Diabetes in Children Phase 4
Completed NCT00005539 - Wisconsin Epidemiological Study of Cardiovascular Disease in Type 1 Diabetes N/A
Completed NCT04689685 - The RADAR Study - Wearable-Based Dysglycemia Detection and Warning in Diabetes
Completed NCT00357890 - Insulin Pump Therapy in Adolescents With Newly Diagnosed Type 1 Diabetes (T1D) N/A